A PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCER
Brief description of study
The purpose of this study is to compare any good and bad effects of using the drug apalutamide (study drug) along with usual radiation therapy to using usual radiation therapy alone. The study drug is a hormone suppression drug. The study drug is FDA approved for the treatment of non-metastatic castration resistant prostate cancer, however the study drug is still considered investigational in this trial setting. The addition of the study drug to usual radiation could shrink your cancer/prevent it from returning, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug should reduce the chance of your cancer growing back compared to the usual approach.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.